Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA + resmetirom
- Development stage
- Preclinical
- Lead developer
- Madrigal Pharmaceuticals
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Subcutaneous
01
Overview
The siRNA + resmetirom combination refers to a suite of six preclinical programs developed by Madrigal Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). These programs, in-licensed from Suzhou Ribo Life Science and Ribocure Pharmaceuticals in February 2026, utilize a dual-mechanism approach: liver-directed small interfering RNA (siRNA) agents designed to silence specific disease-driving proteins (leveraging Ribo's GalSTAR platform) and resmetirom (Rezdiffra), an oral, liver-directed thyroid hormone receptor-beta (THR-β) agonist. While resmetirom is already FDA-approved as a monotherapy, these combinations aim to provide synergistic therapeutic effects by targeting multiple pathways in MASH pathology, such as PNPLA3 silencing in the case of the MGL-0795 program. IND-enabling activities for these programs are expected to begin in 2026.
- Other names
- siRNA/resmetirom combinationsMadrigal Mentalis siRNA programsMadrigal Mentalis pipeline programs
02
Targets
THRA (Thyroid hormone receptor alpha)THRB (Thyroid hormone receptor beta)
Beyond the preview
Go deeper on siRNA + resmetirom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA + resmetirom.